Price
CHART BY
Frequently asked questions
What is Amicus's market capitalization?
The market capitalization of Amicus is $4.38B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Amicus?
Amicus's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.0447. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Amicus's stock?
Currently, 7 analysts cover Amicus's stock, with a consensus target price of $15.25. Analyst ratings provide insights into the stock's expected performance.
What is Amicus's revenue over the trailing twelve months?
Over the trailing twelve months, Amicus reported a revenue of $598.70M.
What is the EBITDA for Amicus?
Amicus's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $42.12M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Amicus?
Amicus has a free cash flow of $9.69M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Amicus have, and what sector and industry does it belong to?
Amicus employs approximately 499 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Amicus's shares?
The free float of Amicus is 302.15M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.38B
- EPS (TTM)
- -$0.0447
- Free Float
- 302.15M
- Revenue (TTM)
- $598.70M
- EBITDA (TTM)
- $42.12M
- Free Cashflow (TTM)
- $9.69M
Pricing
- 1D span
- $14.13$14.25
- 52W span
- $5.51$14.36
Analyst Ratings
The price target is $15.25 and the stock is covered by 7 analysts.
Buy
3
Hold
4
Sell
0
Information
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
- Employees
- 499
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- FOLD
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet